By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162


SEARCH JOBS


Industry
Services
Healthcare






Company News
Agendia BV Release: The New England Journal of Medicine Publishes MINDACT Trial Results Proving The Clinical Utility Of Mammaprint In Assisting Physicians To Identify Early-Stage Breast Cancer Patients Who Can Safely Forgo Chemotherapy 8/25/2016 8:49:21 AM
Agendia BV’s Mammaprint First And Only Genomic Assay To Receive Level 1A Clinical Utility Evidence For Chemotherapy Benefit In Early Breast Cancer Patients 4/19/2016 10:52:22 AM
Agendia BV To Highlight New MammaPrint Data At The 2016 European Breast Cancer Conference As A Prelude To Upcoming MINDACT Trial Findings 3/8/2016 10:34:04 AM
Agendia BV And Partners Receive $6.8 Million From European Commission (EC) To Study Targeted Therapies For Colorectal Cancer 12/16/2015 8:16:51 AM
Agendia BV Highlights Study Showing MammaPrint/BluePrint Tests Predict Response To Current Breast Cancer Chemotherapy And Targeted Therapy Regimens 9/29/2015 11:03:21 AM
Agendia BV Release: NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis 7/28/2015 10:20:51 AM
Agendia BV Co-Founder Wins European Inventor Award For Breast Cancer Test 6/16/2015 10:51:25 AM
Agendia BV Announces Recommendation Of MammaPrint In Germany’s AGO Guidelines, At St. Gallen International Breast Cancer Conference 4/8/2015 10:21:04 AM
Agendia BV Announces Recommendation Of Mammaprint In Germany’s AGO Guidelines, At St. Gallen International Breast Cancer Conference 4/7/2015 10:16:46 AM
Rubicon Genomics, Inc. And Agendia BV Renew Agreement For Use Of TransPLEX Whole Transcriptome RNA Amplification Kits With MammaPrint FFPE Breast Cancer Test 4/7/2015 6:29:12 AM
12345678910
//-->